Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study

Abdulrahman Alharthy¹, Waleed Aletreby², Fahad Faqih³, Abdullah Balhama³, Feisal Alaklobi³, Khaled Alanezi³, Parameaswari Jaganathan⁴, Hani Tamim⁴, Saleh A Alqahtani⁵,⁶, Dimitrios Karakitsos⁷,⁸, Ziad A Memish¹,³,⁹,*

¹Critical Care Department, King Saud Medical City, Riyadh, Saudi Arabia
²Pediatrics Department, King Saud Medical City, Riyadh, Saudi Arabia
³Research & Innovation Centre King Saud Medical City, Ministry of Health, Riyadh, Saudi Arabia
⁴Biostatistics Unit, Clinical Research Institute, American University of Beirut Medical Center, Beirut, Lebanon
⁵Liver Transplantation Unit, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
⁶Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, USA
⁷University of South Carolina, School of Medicine, Columbia, SC, USA
⁸College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
⁹Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA

ARTICLE INFO

Article History
Received 04 September 2020
Accepted 19 September 2020

Keywords
COVID-19
intensive care unit
mortality
active smoking
pulmonary embolism
D-dimers
lactate

ABSTRACT

Background: Since the first COVID-19 patient in Saudi Arabia (March, 2020) more than 338,539 cases and approximately 4996 dead were reported. We present the main characteristics and outcomes of critically ill COVID-19 patients that were admitted in the largest Ministry of Health Intensive Care Unit (ICU) in Saudi Arabia.

Methods: This retrospective study, analyzed routine epidemiologic, clinical, and laboratory data of COVID-19 critically ill patients in King Saud Medical City (KSMC), Riyadh, Saudi Arabia, between March 20, 2020 and May 31, 2020. Severe acute respiratory syndrome coronavirus-2 infection was confirmed by real-time reverse transcriptase polymerase chain reaction assays performed on nasopharyngeal swabs in all enrolled cases. Outcome measures such as 28-days mortality, duration of mechanical ventilation, and ICU length of stay were analyzed.

Results: Three-hundred-and-fifty-two critically ill COVID-19 patients were included in the study. Patients had a mean age of 50.63 ± 13.3 years, 87.2% were males, and 49.4% were active smokers. Upon ICU admission, 56.8% of patients were mechanically ventilated with peripheral oxygen saturation/fraction of inspired oxygen (SpO₂/FiO₂) ratio of 158 ± 32. No co-infections with other endemic viruses were observed. Duration of mechanical ventilation was 16 (IQR: 8–28) days; ICU length of stay was 18 (IQR: 9–29) days, and 28-day mortality was 32.1%. Multivariate regression analysis showed that old age [Odds Ratio (OR): 1.15, 95% Confidence Intervals (CI): 1.03–1.21], active smoking [OR: 3, 95% CI: 2.51–3.66], pulmonary embolism [OR: 2.91, 95% CI: 1.90–4.42], and increased lactate [OR: 3.9, 95% CI: 2.4–4.9], and D-dimers [OR: 2.54, 95% CI: 1.57–3.12] were mortality predictors.

Conclusion: Old age, active smoking, pulmonary embolism, decreased SpO₂/FiO₂ ratio, and increased lactate and D-dimers were predictors of 28-day mortality in critically ill COVID-19 patients.

© 2020 The Authors. Published by Atlantis Press International B.V.

This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

1. INTRODUCTION

The novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) disease (COVID-19) emerged in Wuhan, China, and spread worldwide. Almost 30 million people were affected and the death toll reached 1 million cases thus far [1]. The first case of COVID-19 in Saudi Arabia was confirmed on March 2, 2020, and since then more than 338,539 cases with more than 4996 dead were reported [2,3]. Although most patients present with mild diseases and recover from the infection, life-threatening disease can occur resulting in Intensive Care Unit (ICU) hospitalization. Severe COVID-19 is characterized by Acute Respiratory Distress Syndrome (ARDS), sepsis, multi-system organ failure, hyper-inflammation, neurological and other extra-pulmonary manifestations, and thromboembolic disease [4–14]. Several studies analyzed the factors affecting morbidity and mortality in hospitalized patients with COVID-19 [15–24]. Factors that were correlated with a poor prognosis included old age, the presence of comorbidities such as hypertension, Diabetes Mellitus (DM), morbid obesity, chronic pulmonary disease, coronary artery disease, chronic kidney disease, and malignancies. Laboratory parameters that were linked to a poor outcome were: lymphopenia, and increased levels of inflammatory biomarkers such as C-reactive protein, lactate dehydrogenase, and interleukin-6 amongst others [25–39].
2. MATERIALS AND METHODS

2.1. Study Design and Patients

We retrospectively analyzed critically ill patients with COVID-19 admitted to our COVID-19 designated ICU from March 20, 2020 to May 31, 2020. SARS-CoV-2 infection was confirmed by Real-Time-Polymerase-Chain-Reaction (RT-PCR) assays, performed on nasopharyngeal swabs, using QuantiNova Probe RT-PCR kit (Qiagen, GmbH, Germany) in a Light-Cycler 480 real-time PCR system (Roche, Basel, Switzerland) as described in detail elsewhere [40,41]. Inclusion criteria were: (1) Adult > 18 years old, and (2) ICU admission. Exclusion criteria were: (1) Negative RT-PCR result for COVID-19 in two consecutive samples taken 48 h apart, (2) patients that were transferred to other COVID-19 designated hospitals based on our Ministry of Health (MOH) surge plan, and (3) Health care workers with nosocomial acquisition of SARS-CoV-2 infection. The primary end-point was to investigate risk factors affecting 28-day mortality post-ICU admission. Usual outcome measures such as duration of mechanical ventilation, ICU and hospital length of stay were integrated in the analysis. The study was conducted according to the principles outlined in the Declaration of Helsinki, and was approved by our Institutional Review Board.

2.2. Data Collection and Therapeutic Strategies

COVID-19 patient data recorded in health care records included routine demographic data, medical history, epidemiological exposure, comorbidities, symptoms, signs, laboratory results, coinfections and bacterial cultures results, chest X-rays and Computed Tomographic (CT) scans, applied therapies (i.e., antiviral therapy, corticosteroids, rescue invasive therapies, supportive ICU care), in-hospital complications, and clinical outcomes, were retrospectively analyzed. Pulmonary Embolism (PE) was confirmed by chest computed tomography angiography. Acute Kidney Injury (AKI) was defined as per the “risk”, “injury”, and “failure” criteria [42]; while Continuous Renal Replacement Therapy (CRRT) was performed as per the kidney disease improving global outcomes 2019 guidelines when deemed to be necessary (i.e., anuria, metabolic acidosis, hyperkalemia) [43]. Interventional extracorporeal rescue therapies were performed according to pertinent ICU protocols. For example, Extracorporeal Membrane Oxygenation (ECMO) was applied on patients with refractory hypoxemia [fraction of peripheral oxygen saturation to inspired oxygen saturation (PaO2/FiO2 ratio) < 80 for more than 6 h] based on available resources and practice recommendations [44]. Moreover, several critically ill patients with life-threatening COVID-19 and associated cytokine release syndrome were enrolled in our study regarding the administration of rescue Therapeutic Plasma Exchange (TPE) [45,46]. Upon ICU admission, we administered to all critically ill COVID-19 patients baseline therapy integrating ARDS-net and prone positioning ventilation, empiric antiviral treatment with ribavirin, and interferon beta-1b, as well as antibiotics, corticosteroids, anticoagulation, and other ICU supportive care as per individual clinical case scenario, and according to the Saudi MOH therapeutic protocol [47]. Admission Sequential Organ Function Assessment (SOFA) score, ICU Length of Stay (LOS), hospital LOS, clinical and paraclinical data were registered in all cases. All data were stored in electronic format and retrospectively analyzed.

2.3. Statistical Analysis

Categorical variables are presented as absolute numbers or percentages. Continuous parameters are expressed as mean values ± Standard Deviation (SD) or median values with Interquartile Range (IQR) depending on their distribution. Differences of the studied parameters between survivors and non-survivors COVID-19 patients were evaluated by Wilcoxon Rank sum test for non-parametric data, and the student’s t-test for parametric data as appropriate. Logistic regression was used for each studied parameter over the binary outcome (survival/death) in univariate analysis. The significant predictors for 28-day mortality (p < 0.1) were used for multivariate regression modeling integrating Odds Ratio (OR) with 95% Confidence Intervals (CI). The forward stepwise method was adopted and tested for its goodness of fit by Hosmer–Lemeshow test. Survival analysis was visually presented by Kaplan-Meier curves, while the log-rank test was used to confirm the significance of probability trends for different age groups of COVID-19 patients. All tests were two tailed and considered significant when p-value <0.05. All data were analyzed using Stata/IC (StataCorp. 2015. Stata Statistical Software: Release 14, StataCorp LP, College Station, TX, USA), and SPSS 25.0 (IBM SPSS Statistics for Windows, Version 25.0, IBM Corp., Armonk, NY, USA).

3. RESULTS

The study flowchart is illustrated in Figure 1. Out of 436 critically ill patients with COVID-19, 352 were included in the final analysis. Eighty four patients were excluded due to transfer to other COVID-19 designated hospitals. Of the 352 mechanically ventilated COVID-19 patients that were retrospectively analyzed,
239 survived (67.9%) and 113 patients (32.1%) expired. The main characteristics, clinical parameters, and outcome measures of COVID-19 critically ill patients are presented in Table 1.

The majority of critically ill patients with COVID-19 were males (87.2%) of non-Saudi nationality (88.6%). Prior to hospital admission their most common symptoms were cough (96%) and shortness of breath (90%). Most patients had ABO blood group type O+ (47%), followed by A+ (24%), and B+ (17%) types, respectively. One hundred and eighty-three patients (53.6%) had two or more comorbidities. The most usual comorbidities were hypertension (51.1%) and diabetes mellitus (27.6%). Chest CT scans were performed in 51.1% of cases, and showed bilateral ground-glass opacities with variable pulmonary parenchymal consolidations, which were consistent with COVID-19 pneumonia. No co-infections with other endemic viruses such as the Middle East Respiratory Syndrome Coronavirus (MERS-CoV), or influenza A and B viruses were recorded. However, 25 out of the 352 patients (7.1%) had nosocomial acquired bacterial infections: 15 patients had ventilator associated pneumonia, and ten patients had central-line associated infections. The most common isolated pathogens were: Acinetobacter baumannii, and methicillin resistant staphylococcus aureus. Upon ICU admission, 200 out of the total enrolled patients (56.8%) were intubated and mechanically ventilated (Table 1).

### Table 1  Main parameters and outcome measures of COVID-19 critically ill patients who survived (n = 239) or expired (n = 113)

| Parameters | Total patients (n = 352) | Survivors (n = 239) | Non-survivors (n = 113) | p-value |
|------------|--------------------------|---------------------|-------------------------|---------|
| **General characteristics** | | | | |
| Age (years) | 50.63 ± 13.3 | 49.5 ± 13.1 | 53.1 ± 13.5 | 0.02* |
| Sex (Male: n, %) | 307 (87.2) | 207 (86.6) | 100 (88.5) | 0.6 |
| Nationality (non-Saudis: n, %) | 312(88.6) | 205 (85.8) | 107 (94.7) | 0.014' |
| Height (m) | 1.71 ± 0.6 | 1.71 ± 0.05 | 1.71 ± 0.07 | 0.9 |
| Weight (kg) | 82.5 ± 10.9 | 82.1 ± 11.6 | 83.2 ± 9.2 | 0.2 |
| Body mass index (kg/m²) | 28.2 ± 4 | 27 ± 4 | 28.7 ± 3.9 | 0.1 |
| Active smoker (n, %) | 174 (49.4) | 109 (45.6) | 65 (57.5) | 0.039' |
| **Clinical parameters** | | | | |
| Respiratory rate (cycles/min) | 37.6 ± 2.9 | 37.6 ± 3 | 37.6 ± 2.7 | 0.99 |
| Heart rate (beats/min) | 99.8 ± 12.3 | 98.4 ± 12.2 | 102.7 ± 11.8 | 0.002' |
| Systolic blood pressure (mm Hg) | 132.1 ± 20.3 | 132.7 ± 20.1 | 130.9 ± 20.7 | 0.4 |
| SOFA score upon ICU admission | 5.2 ± 1.9 | 4.3 ± 1.5 | 5.4 ± 1.7 | 0.04' |
| **Comorbidities (n, %)** | | | | |
| No comorbidities | 71 (20.1) | 51 (21.3) | 20 (17.7) | 0.5 |
| One comorbidity | 92 (26.1) | 66 (27.6) | 26 (23) | 0.4 |
| Two or more comorbidities | 189 (53.6) | 122 (51.1) | 67 (59.3) | 0.2 |
| **Prior to hospital admission symptoms** | | | | |
| Cough (n, %) | 336 (95.5) | 227 (95) | 109 (96.5) | 0.7 |
| Fever >38°C (n, %) | 220 (62.5) | 145 (60.7) | 75 (66.4) | 0.4 |
| Shortness of breath (n, %) | 316 (89.8) | 216 (90.4) | 100 (88.5) | 0.7 |
| Myalgia (n, %) | 156 (44.3) | 107 (44.8) | 49 (43.4) | 0.9 |
| **Laboratory parameters** | | | | |
| Hemoglobin (g/dl,12–17) | 12.5 ± 0.6 | 12.2 ± 0.6 | 12.6 ± 0.4 | 0.003' |
| Creatinine (mg/dl, normal: 0.6–1.2) | 1 ± 0.27 | 1 ± 0.25 | 1.1 ± 0.29 | 0.3 |
| Lactate (mmol/l, normal: 1.0–2.5) | 1.81 ± 0.4 | 1.61 ± 0.33 | 2.13 ± 0.34 | 0.0001' |
| INR (normal: 0.8–1.2) | 1.2 ± 0.05 | 1.21 ± 0.049 | 1.19 ± 0.051 | 0.049 |
| White blood cells (cells/mm³, normal: 4–10) | 20.1 ± 3.5 | 20.1 ± 3.6 | 22.2 ± 2.7 | 0.0001' |
| Lymphocytes (10⁹/l, normal: 1.1–3.2) | 0.8 ± 4.1 | 0.8 ± 3.1 | 0.6 ± 2.2 | 0.0001' |
| Platelets (cells/mm³, normal: 150–450) | 226.6 ± 7.4 | 231.3 ± 86.6 | 216.6 ± 31.3 | 0.07 |
| D-dimers (mcg/ml, normal: <1) | 2.6 ± 1.1 | 2.33 ± 0.9 | 3.2 ± 1.2 | 0.0001' |
| ALT (µ/l, normal: 9–50) | 28.4 ± 7.9 | 28.8 ± 7.9 | 27.5 ± 7.7 | 0.15 |
| AST (µ/l, normal range 15–40) | 28.5 ± 11.1 | 28.1 ± 11.1 | 29.5 ± 11.1 | 0.24 |
| Total bilirubin (µmol/l, normal: 0–26) | 15.1 ± 6.9 | 13.3 ± 4 | 13.9 ± 4.1 | 0.25 |
| Albumin (g/l, normal: 35–50) | 25.4 ± 3.9 | 25.3 ± 3.9 | 25.5 ± 3.9 | 0.62 |
| **Ventilation parameters** | | | | |
| Intubated upon ICU admission (n, %) | 200 (56.8) | 114 (47.7) | 86 (76.1) | 0.001' |
| Positive-end-expiratory-pressure (cm-H₂O) | 11.5 ± 2.5 | 11.6 ± 2.6 | 12 ± 2.4 | 0.63 |
| SpO₂/FiO₂ ratio | 157.9 ± 32.1 | 164.1 ± 33.9 | 144.7 ± 23.1 | 0.0001' |
| **Outcome measures** | | | | |
| Symptoms onset to admission (days, IQR) | 9 (7–10) | 9 (7–10) | 8 (6–10) | 0.72 |
| Days on mechanical ventilation | 16 (8–28) | 15 (8–29) | 16 (9–30) | 0.55 |
| ICU length of stay (days, IQR) | 18 (9–29) | 16 (9–30) | 20 (11–33) | 0.046' |
| Hospital length of stay (days, IQR) | 20 (11–31) | 22 (11–32) | 23 (12–39) | 0.3 |

Parametric data are presented as mean ± standard deviation, and non-parametric data are presented as median with IQR. *p < 0.05 were statistically significant. INR, international normalization ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SpO₂/FiO₂, saturation of peripheral oxygen/fraction of inspired oxygen.
The 152 non-intubated patients received a higher level of oxygen support therapies: 100 patients via high flow nasal cannula, 20 via helmet-continuous-positive-airway-pressure, and 35 via Venturi masks. However, approximately 5 days (IQR: 2–7 days) post-ICU admission all patients were mechanically ventilated (100%).

Non-survivors were more frequently active smokers, and had higher SOFA scores on ICU admission, increased lactate, and d-dimers, and decreased lymphocyte counts and saturation of peripheral oxygen/fraction of inspired oxygen ($\text{SpO}_2$/FiO$_2$) ratio compared to survivors (Table 1). During ICU hospitalization, cerebrovascular accidents, which were linked to COVID-19 status, occurred less frequently in survivors compared to non-survivors (2% vs. 7%, $p < 0.05$). The prevalence of PE was higher in non-survivors compared to survivors (15% vs. 7%, $p < 0.05$). AKI developed equally to survivors and non-survivors, while no significant difference was observed in the rate of applied CRRT or other invasive therapies between survivors and non-survivors. However, the putative effect of interventional therapies on survival was not analyzed as this was not an end-point of this study.

In the univariate logistic regression analysis, eight variables had significant effect on 28-day mortality. These variables were: age, ICU length of stay, $\text{SpO}_2$/FiO$_2$ ratio, white blood cells and lymphocytes counts, d-dimers and lactate levels, presence of PE, and active smoker status; hence, these parameters were also included in the multivariate regression analysis. These models are both illustrated in Table 2. Hosmer–Lemeshow test confirmed that the model was well fit with a high sensitivity 91.5% and specificity 95.2% in predicting mortality risk factors along with a positive predictive value of 89.8%, and negative predictive value of 96%, respectively. Five parameters emerged as significant predictors of 28-day mortality in this cohort of COVID-19 critically ill patients: old age, active smoker status, presence of PE, increased serum lactate and d-dimers (Table 2). Kaplan-Meier curves for 28-day mortality that were observed in different age groups of this cohort of critically ill COVID-19 patients are illustrated in Figure 2. The mean survival time post-ICU admission in different age groups is also presented in Table 3. The significance of survival trends that were observed in different age groups was confirmed by Mantel-Cox log-rank test ($p = 0.005$). Hence, the worst survival rates were observed in the group 51–60 years of age followed by the group 41–50 years of age (Figure 2 and Table 3).

### 4. DISCUSSION

The main findings of this retrospective study can be summarized as follows. We found that old age, presence of PE, and increased lactate and d-dimers were associated with poor prognosis in mechanically

---

**Table 2** Univariate and multivariate logistic regression models for 28-day mortality in critically ill patients with COVID-19

| Parameters                  | Univariate analysis | Multivariate analysis |
|-----------------------------|---------------------|-----------------------|
|                             | Odds ratio (95% confidence intervals) | $p$-value | Odds ratio (95% confidence intervals) | $p$-value |
| Age (years)                 | 1.06 (1.01–1.09)    | 0.020*                | 1.15 (1.03–1.21)    | 0.022*    |
| ICU length of stay (days)   | 1.07 (1.03–1.14)    | 0.001*                | 1.11 (1.06–1.16)    | 0.069     |
| $\text{SpO}_2$/FiO$_2$ ratio| 0.93 (0.82–0.97)    | 0.001*                | 0.94 (0.91–0.97)    | 0.009*    |
| White blood cells (10$^9$/l)| 1.20 (1.14–1.33)    | 0.001*                | 1.26 (1.06–1.51)    | 0.061     |
| Lymphocytes (10$^9$/l)      | 0.95 (0.91–0.98)    | 0.001*                | 0.95 (0.92–0.97)    | 0.052     |
| d-dimers (mcg/ml)           | 2.20 (1.70–2.70)    | 0.001*                | 2.54 (1.57–3.12)    | 0.011*    |
| Lactate (mmol/l)            | 3.1 (2.2–4.7)       | 0.001*                | 3.9 (2.4–4.9)       | 0.035*    |
| Pulmonary embolism          | 2.80 (1.92–3.31)    | 0.003*                | 2.91 (2.65–3.36)    | 0.019*    |
| Active smoking              | 2.6 (2.03–3.50)     | 0.037*                | 3.00 (2.51–3.66)    | 0.025*    |

*p < 0.05 were statistically significant.

---

**Figure 2** Kaplan-Meier survival curves integrating different age groups of COVID-19 patients that were hospitalized in the intensive care unit (ICU).
ventilated patients with COVID-19, which is in accordance with previous reports [15–39]. An increased prevalence of thromboembolic disease was reported in critically ill COVID-19 patients and is a poor prognostic marker [5–7,12,48,49]. Accordingly, increased levels of d-dimers were associated with poor prognosis in critically ill COVID-19 patients [24]. Hypercoagulability, vascular dysfunction, and hyperinflammation were suggested underlying mechanisms promoting thromboembolic disease in severe COVID-19 [5–7,12,48–50]. SARS-CoV-2 can bind to the ACE-2 receptors that are expressed on type II pneumocytes and vascular endothelial cells in the lung, and thus cause direct injury to the pulmonary vasculature [50]. The development of PE along with the lung parenchymal inflammation could signify a “dual-hit” underlying mechanism, which in turn may result in refractory ARDS [51].

The presence of comorbidities and old age are poor prognostic indicators in hospitalized COVID-19 patients [4,9–11,16–19,31,32,34–39]. We found higher mortality rates in elderly patients; however, middle aged patients (41–50 years old) had also relatively high rates [4]. The mean age of our critically ill COVID-19 patients was younger compared to other studies [1–4,10,29–39]. This may be partially explained by the fact that the mean age of the general population in our country is relatively lower (≥65 years is <3%); compared to Asian, European, and American countries that were affected by the pandemic. Another possible explanation is that SARS-CoV-2 can also affect younger individuals with detrimental results [4,10,29–39]. These patients may present with severe extra-pulmonary manifestations such as brain infarctions [32]. In our study, although the incidence of stroke was higher in non-survivors, these were mainly elderly patients with other comorbidities. Moreover, we could not perform a detailed analysis of the neurological findings due to incomplete brain imaging information that were available during the study period.

Data from the UK and North America showed that black patients with COVID-19 had increased odds of death [53,54]. In our study, most patients were of Asian and Middle Eastern ethnic origin, and the vast majority was of non-Saudi nationality. We found that the majority of patients had ABO blood group type O+ (47%), but no correlation of ABO blood group type with mortality existed as it was previously suggested [55–57]. The incidence of hospital acquired bacterial infections, which was observed in this retrospective series, was comparable to other reports [25–39]. We did not find any co-infections with other endemic viruses such as MERS-CoV, which is in accordance with a previous Saudi Arabia based study [58]. Notwithstanding, the putative benefit from past exposure to MERS-CoV cannot be definitely excluded since a 50% genomic similarity between these two beta-coronaviruses exists. Also, we found that active smoking was a predictor of mortality in critically ill COVID-19 patients. Anecdotal reports advocated that smoking was partially protective for COVID-19 in the beginning of the pandemic [59–61]. However, our results further confirmed recent studies that smokers and patients with chronic obstructive pulmonary disease have increased odds of poor outcome when infected by SARS-CoV-2 [16,17,28,29,62,63].

This study has inherent limitations mainly due to its retrospective, single-center design. Also, the effect of applied interventional extra-corporeal therapies such as ECMO or TPE on survival was not studied as this was not an end-point of the study. The latter was focused mainly on analyzing routine epidemiologic and clinical data of critically ill COVID-19 patients. In contrast to previous reports, we did not exclude critically ill patients that expired within the first 48 h after ICU admission as we wished to include the effect of fulminant COVID-19 and/or the occurrence of severe post-admission complications in our analysis [9,39]. Also, other clinical and paraclinical data such as mechanical ventilation parameters, detailed laboratory and imaging data were not available in all cases, which prevented a more meaningful subgroup analysis. The 28-day post-ICU admission mortality rate was 32.1%, which is relatively lower compared to initial reports in mechanically ventilated COVID-19 patients from China, Europe, and the US [4,9–11,16,37–39]. Notably, AKI that was previously identified as an independent predictor of mortality in critically ill COVID-19 patients did not emerge as a factor influencing mortality in our study [27–32,34–39]. We are uncertain whether this might be explained by the prompt application of interventional therapies such as CRRT or it could be attributed to the clinical notion that COVID-19 may not necessarily result in AKI [33]. Despite the aforementioned limitations, we found that old age, decreased SpO2/FiO2 ratio, and increased lactate, and d-dimers along with higher prevalence of PE, and active smoking were all poor prognostic factors in critically ill COVID-19 patients. Surely, different factors affecting mortality were identified based on the various studies’ designs thus far. In that sense, more prospective studies are required to analyze all putative factors affecting mortality in critically ill patients with COVID-19.

**CONFLICTS OF INTEREST**

Given his role as Editor in Chief, Ziad Memish had no involvement in the peer-review of this article and has no access to any information regarding its peer-review. Full responsibility for the editorial process for this article was delegated to Dr. Shahul Ebrahim. All other authors have no conflicts of interest to disclose.

**AUTHORS’ CONTRIBUTION**

AA contributed in idea, concept, proposal, data interpretation, manuscript writing, and final approval. WA contributed in idea, concept, proposal, data collection, data entry, data analysis, manuscript writing, and final approval. FF, AB, FA, KA, PJ and HT contributed in idea, concept, proposal, data collection, data analysis, manuscript writing, and final approval. SAA and DK contributed in data interpretation, manuscript writing, critical reviewing, and final approval. ZAM contributed in idea, concept, data interpretation, manuscript writing, critical reviewing, and final approval.

---

**Table 3** Mean survival time (days) post intensive care unit admission, in different age groups of COVID-19 critically ill patients

| Age group in years | Mean survival time (days) (mean ± standard error) | 95% Confidence interval |
|--------------------|---------------------------------------------------|------------------------|
| 18–30              | 26.1 ± 1.2                                        | 23.6–28.6              |
| 31–40              | 19.7 ± 1.3                                        | 17.2–22.3              |
| 41–50              | 19.0 ± 1.1                                        | 16.9–21.1              |
| 51–60              | 18.4 ± 1.1                                        | 16.3–20.6              |
| >60                | 20.8 ± 0.92                                       | 19.1–22.6              |
| Overall            | 20.0 ± 0.03                                       | 18.9–21.1              |
REFERENCES

[1] World Health Organization. Coronavirus Disease (COVID-19) – events as they happen. 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen.

[2] COVID-19 dashboard: Saudi Arabia. 2020. Available from: https://covid19.moh.gov.sa (accessed September 2, 2020).

[3] Saudi-Center for Disease Prevention and Control. Information about Coronavirus Disease Covid-19. 2020. Available from: https://covid19.cdc.gov.sa/ (accessed September 2, 2020).

[4] Grasselli G, Zangrillo A, Zanella A, Antonelli M, Gabricini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020;323:1574–81.

[5] Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020;18:1421–4.

[6] Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gomers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7.

[7] Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18:1094–9.

[8] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382;1708–20.

[9] Zhou F, yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.

[10] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA 2020;323:1239–42.

[11] Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475–81.

[12] Fraissé M, Logre E, Pajot O, Mentec H, Plantefève G, Contou D. Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study. Critical Care 2020;24:275.

[13] Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 2020;awa240.

[14] Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med 2020;382:e38.

[15] Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58:1021–8.

[16] Li LQ, Huang T, Wang YQ, Liang Y, Huang TB, Zhang HY, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020;92:577–83.

[17] Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almehmadi M, Alqahtani AS, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One 2020;15:e0233147.

[18] Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr 2020;14:395–403.

[19] Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146;110–8.

[20] Tian S, Liu H, Liao M, Wu Y, Yang C, Cai Y, et al. Analysis of mortality in patients with COVID-19: clinical and laboratory parameters. Version 2. Open Forum Infect Dis 2020;7:ofaa152.

[21] Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect 2020;81:e6–e12.

[22] Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020;5:802–10.

[23] Bhattacharya PK, Ghasemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle Region — case series. N Engl J Med 2020;382:2012–22.

[24] Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020;18:1324–9.

[25] Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost 2020;18:1469–72.

[26] Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 2020;55;2000524.

[27] Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:848–6.

[28] Xie J, Covassinn N, Fan Z, Singh P, Gao W, Li G, et al. Association between hypoxemia and mortality in patients with COVID-19. Mayo Clin Proc 2020;95:1138–47.

[29] Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism 2020;108:154262.

[30] Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020;97:829–38.

[31] Sun H, Ning R, Tao Y, Yu C, Deng X, Zhao C, et al. Risk factors for mortality in 244 older adults with COVID-19 in Wuhan, China: a retrospective study. J Am Geriatr Soc 2020;68:E19–E23.

[32] Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:848–6.

[33] Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol 2020;51:43–8.

[34] Hu L, Chen S, Fu Y, Gao Z, Long H, Wang JM, et al. Risk factors associated with clinical outcomes in 323 coronavirus disease 2019 (COVID-19) hospitalized patients in Wuhan, China. Clin Infect Dis 2020;ciaa539.
[35] Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020;395;1763–70.

[36] Ciceri F, Castagna A, Rovere-Querini P, De Cobelli F, Ruggeri A, Galli L, et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol 2020;217;108509.

[37] Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020;21;904–13.

[38] Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368;m1091.

[39] Xu J, Yang X, Yang L, Zou X, Wang Y, Wu Y, et al. Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China. Crit Care 2020;24;394.

[40] World Health Organization. Laboratory assessment tool for laboratories implementing COVID-19 virus testing. 2020. Available from: https://www.who.int/publications/i/item/laboratory-assessment-tool-for-laboratories-implementing-covid-19-virus-testing.

[41] Chan JFW, Yip CCY, To KKW, Tang THC, Wong SCY, Leung KH, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR Assay validated in vitro and with clinical specimens. J Clin Microbiol 2020;58:e00310–e20.

[42] Ostermann M, Chang RWS. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007;35;1837–43; quiz 1852.

[43] Wang AYM, Akizawa T, Bavanandan S, Hamano T, Liew A, Lu KC, et al. 2017 Kidney disease: improving global outcomes (KDIGO) chronic kidney disease-mineral and bone disorder (CKD-MBD) Guideline update implementation: Asia Summit Conference Report. Kidney Int Rep 2019;4;1523–37.

[44] Savarimuthu S, BinSaedi J, Harky A. The role of ECOMO in COVID-19: can it provide rescue therapy in those who are critically ill? J Card Surg 2020;35;1298–301.

[45] Faqhi A, Alharthy A, Alodat M, Kutsoogianis DJ, Brindley PG, Karakitsos D. Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: a pilot study. J Crit Care 2020;S0883-9441(20)30602-X.

[46] Faqhi F, Alharthy A, Alodat M, Asad D, Aletreby W, Kutsoogianis DJ, et al. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): a structured summary of a randomized controlled trial study protocol. Version 2. Trials 2020;21;506.

[47] Saudi Ministry of Health. Coronavirus diseases 19 (COVID-19) guidelines (revised version 1.7). 2020. Available from: https://covid19.moh.gov.sa.

[48] Paranipe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, et al. Association of treatment dose anticoagulation with in-Hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 2020;76;123–4.

[49] Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18;1023–6.

[50] Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;395;1417–8.

[51] Alharthy A, Faqhi F, Memish ZA, Karakitsos D. Lung injury in COVID-19-an emerging hypothesis. ACS Chem Neurosci 2020;11;2156–8.

[52] Yaghi S, Ishida K, Torres J, Mac Gory B, Raz E, Humbert K, et al. SARS-CoV-2 and stroke in a New York Healthcare System. Stroke 2020;51;2002–11.

[53] Mohan A, Tiwari P, Bhatnagar S, Patel A, Maurya A, Dar L, et al. Clinico-demographic profile & hospital outcomes of COVID-19 patients admitted at a tertiary care centre in north India. Indian J Med Res 2020;152;61–9.

[54] Perez-Guzman PN, Daunt A, Mukherjee S, Crook P, Forlano R, Kont MD, et al. Clinical characteristics and predictors of outcomes of hospitalized patients with COVID-19 in a multi-ethnic London NHS Trust: a retrospective cohort study. Clin Infect Dis 2020;cia1091.

[55] Gérard C, Maggipinto G, Minon JM. COVID-19 and ABO blood group: another viewpoint. Br J Haematol 2020;190;e93–4.

[56] Göker H, Aladağ Karakulak E, Demiroğlu H, Ayaz Ceylan ÇM, Büyükaşık Y, Inkaya AC, et al. The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. Turk J Med Sci 2020;50;679–83.

[57] Zietz M, Zucker JE, Tatonetti NP. Testing the association between blood type and COVID-19 infection, intubation, and death. medRxiv 2020;2020.04.08.20058073.

[58] Barry M, AlMohaya A, AlHiiji A, Akkielah L, AlRajhi A, Almajid F, et al. Clinical characteristics and outcome of hospitalized COVID-19 patients in a MERS-CoV endemic area. J Epidemiol Glob Health 2020;10;214–21.

[59] Leung JM, Sin DD. Smoking. ACE-2 and COVID-19: ongoing controversies. Eur Respir J 2020;56;2001579.

[60] Cattaruzza MS, Zagà V, Gallus S, D’Argenio P, Gorini G. Tobacco smoking and COVID-19 pandemic: old and new issues. A summary of the evidence from the scientific literature. Acta Biomed 2020;91;106–12.

[61] Russo P, Bonassi S, Giaconci R, Malavolta M, Tomino C, Maggi F. COVID-19 and smoking: is nicotine the hidden link? Eur Respir J 2020;55;2001116.

[62] van Zyl-Smit RN, Richards G, Leone FT. Tobacco smoking and COVID-19 infection. Lancet Respir Med 2020;8;664–5.

[63] Lu KC, et al. 2017 Kidney disease: improving global outcomes (KDIGO) chronic kidney disease-mineral and bone disorder guideline update implementation: Asia Summit Conference Report. Kidney Int Rep 2019;4;1523–37.

[64] Savarimuthu S, BinSaedi J, Harky A. The role of ECOMO in COVID-19: can it provide rescue therapy in those who are critically ill? J Card Surg 2020;35;1298–301.

[65] Faqhi A, Alharthy A, Alodat M, Kutsoogianis DJ, Brindley PG, Karakitsos D. Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: a pilot study. J Crit Care 2020;S0883-9441(20)30602-X.

[66] Faqhi F, Alharthy A, Alodat M, Asad D, Aletreby W, Kutsoogianis DJ, et al. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): a structured summary of a randomized controlled trial study protocol. Version 2. Trials 2020;21;506.

[67] Saudi Ministry of Health. Coronavirus diseases 19 (COVID-19) guidelines (revised version 1.7). 2020. Available from: https://covid19.moh.gov.sa.